COVID-19 infection in a pediatric kidney transplant population: A single-center experience.
COVID-19
infectious risk
pediatric kidney transplant
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
03
02
2021
received:
12
10
2020
accepted:
19
03
2021
pubmed:
5
4
2021
medline:
4
6
2021
entrez:
4
4
2021
Statut:
ppublish
Résumé
The clinical course of SARS-CoV-2 in the pediatric kidney transplant population is not well described. We performed a retrospective cohort study of a pediatric kidney transplant population at a New York transplant center. Baseline characteristics and clinical course of patients with SARS-CoV-2 positivity (Ab or PCR) were described, and comparison between COVID-positive and COVID-negative transplant patients was performed. Twenty-two patients had COVID-19 IgG testing performed, eight of whom also had PCR testing. 23% of our cohort had evidence of COVID-19 infection. Four patients had positive IgG only, and one patient had a positive PCR. All five patients with a positive COVID test were female. Two patients had COVID-19 symptoms, which were mild. Of the symptomatic patients, one had a positive PCR at time of symptoms, while the other had a negative PCR during symptoms but subsequently had positive IgG. As compared to patients with COVID-19 negative results, those with COVID-19 positivity were significantly more likely to have a known COVID-19 exposure, and were also more likely to be female. There was no significant difference in time from transplant between the groups. Those in the COVID-positive group had higher baseline antimetabolite dose and CNI troughs, although these did not reach statistical significance. Pediatric kidney transplant recipients are at risk for development of COVID-19 infection. While this population may be more at risk for SARS-CoV-2 infection due to their immunosuppressed status, their clinical course appears mild and similar to a healthy pediatric population.
Sections du résumé
BACKGROUND
The clinical course of SARS-CoV-2 in the pediatric kidney transplant population is not well described.
METHODS
We performed a retrospective cohort study of a pediatric kidney transplant population at a New York transplant center. Baseline characteristics and clinical course of patients with SARS-CoV-2 positivity (Ab or PCR) were described, and comparison between COVID-positive and COVID-negative transplant patients was performed.
RESULTS
Twenty-two patients had COVID-19 IgG testing performed, eight of whom also had PCR testing. 23% of our cohort had evidence of COVID-19 infection. Four patients had positive IgG only, and one patient had a positive PCR. All five patients with a positive COVID test were female. Two patients had COVID-19 symptoms, which were mild. Of the symptomatic patients, one had a positive PCR at time of symptoms, while the other had a negative PCR during symptoms but subsequently had positive IgG. As compared to patients with COVID-19 negative results, those with COVID-19 positivity were significantly more likely to have a known COVID-19 exposure, and were also more likely to be female. There was no significant difference in time from transplant between the groups. Those in the COVID-positive group had higher baseline antimetabolite dose and CNI troughs, although these did not reach statistical significance.
CONCLUSIONS
Pediatric kidney transplant recipients are at risk for development of COVID-19 infection. While this population may be more at risk for SARS-CoV-2 infection due to their immunosuppressed status, their clinical course appears mild and similar to a healthy pediatric population.
Identifiants
pubmed: 33813782
doi: 10.1111/petr.14018
pmc: PMC8250351
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14018Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Transplantation. 2020 Nov;104(11):2208-2214
pubmed: 32496357
Transpl Infect Dis. 2021 Feb;23(1):e13423
pubmed: 32701196
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974
J Clin Virol. 2020 Jun;127:104377
pubmed: 32361323
Infect Genet Evol. 2020 Oct;84:104485
pubmed: 32739464
J Infect. 2020 Jul;81(1):e61-e66
pubmed: 32335173
Am J Transplant. 2020 Jul;20(7):1819-1825
pubmed: 32351040
EClinicalMedicine. 2020 Sep;26:100527
pubmed: 32923992
Children (Basel). 2020 Jul 01;7(7):
pubmed: 32630212
J Clin Invest. 2020 Nov 2;130(11):5967-5975
pubmed: 32730233
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Pediatrics. 2020 Oct;146(4):
pubmed: 32680880
Eur J Pediatr. 2020 Aug;179(8):1315-1323
pubmed: 32495147
J Am Soc Nephrol. 2020 Oct;31(10):2413-2423
pubmed: 32847984
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Transpl Infect Dis. 2020 Oct;22(5):e13349
pubmed: 32500922
Crit Care. 2020 Aug 12;24(1):496
pubmed: 32787887
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
Am J Transplant. 2020 Nov;20(11):3140-3148
pubmed: 32649791